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Clopidogrel is the mainstay for antiplatelet treatment after percutaneous coronary intervention (PCI). 
The relationship of platelet reactivity and genetic polymorphism with clinical outcomes with newer-
generation drug-eluting stents is unclear. We analysed 4,587 patients for the most powerful single-
nucleotide polymorphisms (CYP2C19, CYP2C9, ABCB1, PON1, and P2Y12) related to on-treatment 
platelet reactivity (OPR). The optimal cut-off value of high OPR for major adverse thrombotic events 
was 266. CYP2C19 was significantly associated with high OPR and the number of CYP2C19*R (*2 
or *3) alleles was proportional to the increased risk of high OPR. Death, myocardial infarction (MI), 
stroke, stent thrombosis, and bleeding events were assessed during a 1-year follow-up period. Primary 
endpoints were death and non-fatal MI. The cumulative 1-year incidence of death and stent thrombosis 
was significantly higher in patients with CYP2C19*2/*2, CYP2C19*2/*3, and CYP2C19*3/*3 (Group 3) 
than in patients with CYP2C19*1/*1 (Group 1). Multivariate Cox proportional hazard model showed 
that cardiac death risk was significantly higher in Group 3 than in Group 1 (hazard ratio 2.69, 95% 
confidence interval 1.154–6.263, p = 0.022). No association was reported between bleeding and OPR. 
Thus, CYP2C19 may exert a significant impact on the prognosis of PCI patients even in the era of newer-
generation drug-eluting stents.
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Strong platelet inhibition using dual antiplatelet therapy (DAPT) has been the mainstay for the prevention of 
adverse thrombotic events after percutaneous coronary intervention (PCI). DAPT includes the combination 
of a P2Y12 inhibitor and low-dose aspirin. The newer, more potent P2Y12 inhibitors (prasugrel and ticagre-
lor) have been shown to reduce recurrent ischemic events, especially in patients with acute coronary syndrome 
(ACS), but adverse bleeding events have been a concern. Current guidelines prefer prasugrel or ticagrelor for ACS 
patients undergoing PCI and recommend clopidogrel in the non-ACS setting1,2. However, the concerns related 
to increased cost, adverse bleeding events, older age, and other comorbidity may limit the use of ticagrelor or 
prasugrel. Hence, clopidogrel remains the most widely used treatment regimen for PCI.
It is interesting that the East Asian population show different laboratory and clinical thrombogenicity and 
bleeding characteristics as compared with the Western populations3. The “East Asian paradox” refers to the 
increased prevalence of high on-treatment platelet reactivity (OPR) but similar or lower thrombotic event rates 
after PCI in East Asian patients and has raised questions over the optimal antiplatelet strategy for the East Asian 
patients4. The proposed mechanism underlying these phenomena includes differences in genetic predisposi-
tion such as the higher prevalence of CYP2C19 loss-of-function alleles, which has been observed in East Asian 
patients5. These data indicate that the discrepancy between thrombogenicity characteristics and genotyping may 
affect clinical outcomes after PCI. A recent meta-analysis has demonstrated that CYP2C19 genotype may con-
tribute to worse cardiovascular outcomes in the Asian population as compared with the Western population, 
particularly after PCI6.
The present study examined the single nucleotide polymorphisms (SNPs) of five genes (CYP2C19 as well as 
CYP2C9, ABCB1, paraoxonase-1 [PON1], and P2Y12), which were reported to be associated with clopidogrel 
absorption, metabolism, activation, and resistance7–11. Although several studies have examined the relationship 
between OPR as well as genotypes and clinical outcomes in East Asian patients, these studies were limited in 
size and patient populations12–14. Moreover, in the era of newer-generation, drug-eluting stents (DES), it is still 
unclear whether OPR and its associated genetic polymorphisms may affect clinical outcomes, including both 
ischemic and bleeding events. The present study, therefore, enrolled approximately 5,000 patients undergoing 
PCI and determined the relationship between OPR as well as genotypes and the subsequent major adverse events 
in Korean patients.
Results
Baseline characteristics. Baseline characteristics of the study population are presented in Table S1. Briefly, 
2,432 (59.97%) patients had index PCI because of ACS and 834 (18.18%) patients had multivessel disease. About 
two-thirds (4,386; 63.58%) of the implanted stents were second-generation DES with durable polymers. In 
addition, 2,234 (32.39%) stents were third-generation DES with biodegradable polymers. Bare metal stents and 
first-generation DES were rarely used. Mean P2Y12 reaction unit (PRU) with DAPT was 213.88 ± 76.19.
Defining high on-treatment platelet reactivity (OPR). To explore the relationship between OPR and 
clinical outcomes, major adverse thrombotic event (MATE) and bleeding event rates were compared after equally 
dividing patients into four groups according to their PRU values (Fig. S1). MATE rates were higher in groups 
with higher PRU values, but no significant difference was observed in the bleeding rate among different groups. 
Next, we determined the optimal PRU cut-off values for MATE prediction after PCI. The receiver operating char-
acteristic (ROC) curve showed that the area under the curve (AUC) of PRU to predict 1-year MATE was 0.6221 
(Fig. S2). The Youden index indicated that the optimal PRU cut-off value was 266. With this cut-off value, the 
sensitivity and specificity for MATE was 44.00% and 75.25%, respectively. Therefore, a PRU > 266 was defined 
as high OPR.
Prevalence of clopidogrel metabolism-related gene variants. Of the five SNPs assessed, PON1 gene 
variants were the most common (87.97%, Table 1). The prevalence of CYP2C19 loss-of-function alleles (except 
for CYP2C19*1/*1 and CYP2C19*1/*17) was 62.11% and CYP2C19*1/*2 was the most common (35.10%). 
The prevalence of the complete loss of a normal allele (CYP2C19*2/*17, CYP2C19*2/*2, CYP2C19*2/*3, 
CYP2C19*3/*17, and CYP2C19*3/*3) was 14.79%. The prevalence of CYP2C19 gain-of-function alleles 
(CYP2C19*1/*17, CYP2C19*2/*17, and CYP2C19*3/*17) was only 2.14%, while that of CYP2C9, ABCB1, and 
P2Y12 gene variants was 7.87%, 59.34%, and 24.06%, respectively.
Relationship between gene variants and OPR. After adjustment, multivariate analysis indicated that 
only CYP2C19 gene variants were an independent risk predictor for high OPR. CYP2C19*3/*3 had the highest 
odd ratio (OR) for high OPR risk (adjusted OR 7.59, 95% confidence interval [CI] 4.135–13.935, p < 0.0001). The 
number of CYP2C19*R (*2 or*3) alleles proportionally increased the risk of high OPR (*1/*R, adjusted OR 2.08, 
95% CI 1.749–2.466, p < 0.0001; *R/*R, adjusted OR 4.14, 95% CI 3.339–5.141, p < 0.0001). Therefore, 15.4% of 
patients with CYP2C19*1/*1 and 42.5% of patients with CYP2C19*R/*R had a high OPR (Fig. S3). It is interest-
ing that the presence of the gain-of-function allele (CYP2C19*17) had not significant effect on OPR (Fig. S4). No 
significant difference was observed in the average PRU values between patients with or without CYP2C19*17. 
The prevalence of high OPR was the lowest in patients with CYP2C19*17.
Relation between CYP2C19 polymorphism and clinical outcome. The gain-of-function allele 
CYP2C19*17 may be a confounder; hence, patients with CYP2C19*17 were excluded, while the remaining 
patients were categorised into three groups: Group 1, patients with CYP2C19*1/*1, n = 1,682; Group 2, patients 
with CYP2C19*1/*R (R represent 2 or 3), n = 2,171; and Group 3, patients with CYP2C19*R/*R, n = 636. 
Baseline characteristics and procedural details of each group are shown in Table 2. As expected, the average PRU 
of Group 2 was higher than that of Group 1 and lower than that of Group 3. The proportion of patients who had 
already undergone coronary artery bypass graft was significantly lower in Group 3 (p = 0.028). Furthermore, the 
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average serum creatinine level was significantly higher in Group 3 (p < 0.001). However, no significant difference 
was observed in the baseline characteristics among the three groups.
Overall and grouped in-hospital events and 1-year cumulative rates of clinical events are shown in Table S2 
and Table 3, respectively. In the primary endpoints, the cumulative rate of death (all death and cardiac death) 
was significantly higher in patients with CYP2C19*R/*R (Group 3) as compared to the other groups, but no 
significant difference was observed in the cumulative rate of non-fatal myocardial infarction (MI) among groups. 
In the secondary endpoints, the cumulative rate of definite stent thrombosis was significantly higher in Group 
3 and no significant difference was reported in the cumulative rates of MATE or bleeding events (defined as 
Bleeding Academic Research Consortium [BARC] 3/4/5). A multivariate Cox proportional hazard model showed 
that patients with CYP2C19*R/*R (Group 3) had a higher risk of cardiac death as compared with patients with 
CYP2C19*1/*1 (Group 1) (adjusted hazard ratio [HR] 2.79, 95% CI 1.08–7.19, p = 0.006, Fig. 1 and Table 4). In 
addition, old age, low haemoglobin, and low left ventricular ejection fraction were independent predictors for 
cardiac death.
Discussion
The main findings from Analysis 1 are as follows: (1) higher OPR was significantly associated with a higher 
incidence of thrombotic events after PCI; the optimal cut-off value for high OPR was a PRU value of 266; 
and (2) among five SNPs, only CYP2C19 gene variants was associated with the increased risk of high OPR in 
a dose-dependent manner. The main findings from Analysis 2 are as follows: (1) the 1-year incidence rate of 
death (all death and cardiac death) was significantly higher in patients with CYP2C19*R/*R (Group 3) as com-
pared to other groups; (2) the incidence of stent thrombosis was higher in patients with CYP2C19*R/*R; and (3) 
CYP2C19*R/*R was an independent risk predictor for cardiac death.
The present study proposed that a PRU value of 266 was the optimal cut-off value for high OPR for MATE 
(Fig. S2). OPR has been associated with adverse cardiovascular events after PCI15. The recent large ADAPT-DES 
trial demonstrated that high OPR was not only an independent risk predictor for ischemic events but also a 
protective factor for bleeding events after DES implantation16. In addition, the collaborative analysis of 17 recent 
trials demonstrated that OPR was related with higher risk of stent thrombosis, bleeding, and subsequent mortal-
ity17,18. In comparison with the Western patients, the East Asian patients showed different platelet reactivity pro-
files with a higher prevalence of high OPR, suggestive of the higher cut-off values to define high OPR (252–274 
versus 208–240 PRU)3,19,20. It is interesting that the East Asian patients, in spite of their higher OPR, showed 
similar or lower ischemic event risk as compared with the Western patients; this phenomenon is called as the 
“East Asian Paradox”.
N (%) Adjusted OR (95% CI)* p-value
CYP2C19
*1/*1 1682 (36.7) Reference
*1/*17 56 (1.2) 1.71 (0.906–3.245) 0.10
*1/*2 1610 (35.1) 2.01 (1.675–2.418) <0.01
*1/*3 561 (12.2) 2.31 (1.818–2.933) <0.01
*1/*R 2227 (48.6) 2.08 (1.749–2.466) <0.01
*2/*17 33 (0.7) 2.43 (1.094–5.396) 0.03
*2/*2 342 (7.5) 3.86 (2.943–5.062) <0.01
*2/*3 245 (5.3) 4.43 (3.265–6.022) <0.01
*3/*17 9 (0.2) 1.90 (0.375–9.646) 0.44
*3/*3 49 (1.1) 7.59 (4.135–13.935) <0.01
*R/*R 678 (14.8) 4.14 (3.339–5.141) <0.01
CYP2C9
*1/*1 4226 (92.1) Reference
*1/*3 356 (7.8) 0.76 (0.574–1.005) 0.80
*3/*3 5 (0.1) 0.78 (0.083–7.217) 0.90
PON1
RR 552 (12.0) Reference
QR 2172 (47.4) 0.83 (0.659–1.035) 0.08
QQ 1863 (40.6) 0.90 (0.719–1.136) 0.95
ABCB1
CC 1865 (40.7) Reference
CT 2101 (45.8) 1.05 (0.898–1.220) 0.36
TT 621 (13.5) 0.95 (0.758–1.189) 0.49
P2Y12
GG 3483 (75.9) Reference
GT 1007 (22.0) 1.00 (0.837–1.183) 0.52
TT 97 (2.1) 1.19 (0.746–1.900) 0.46
Table 1. Prevalence of genetic variants and their risk analysis for high OPR. *Odd ratio (OR) with 95% 
confidence interval (CI) was adjusted for age, sex, body mass index, current smoker, diabetes mellitus, prior 
coronary artery bypass graft, acute coronary syndrome, multivessel involvement, haemoglobin level, and 
creatinine level.
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Group 1 (*1/*1) n = 1682 Group 2 (*1/*R) n = 2171 Group 3 (*R/*R) n = 636 p-value
Age (year) 64.4 ± 10.7 64.53 ± 10.67 64.41 ± 10.95 0.93
Men, n (%) 1186 (70.5) 1545 (71.2) 441 (69.3) 0.78
Body mass index (kg/m2) 24.65 ± 3.11 24.6 ± 3.14 24.66 ± 3.12 0.86
Current smoker, n (%) 422 (25.1) 564 (26.0) 163 (25.6) 0.83
Hypertension, n (%) 1065 (63.3) 1374 (63.3) 385 (60.5) 0.32
Diabetes mellitus, n (%) 534 (31.8) 733 (33.7) 201 (31.6) 0.67
Hyperlipidaemia, n (%) 621 (36.9) 813 (37.5) 236 (37.2) 0.84
Prior myocardial infarction, n (%) 117 (7.0) 161 (7.4) 40 (6.3) 0.80
Prior PCI, n (%) 239 (14.2) 300 (13.8) 91 (14.3) 0.95
Prior CABG, n (%) 35 (2.1) 34 (1.6) 5 (0.8) 0.03
Prior cerebrovascular accident, n (%) 118 (7.0) 171 (7.9) 41 (6.5) 1.00
Diagnosis at the index PCI
Stable angina, n (%) 682 (40.6) 870 (40.1) 248 (39.0)
0.24
Unstable angina, n (%) 518 (30.8) 691 (31.8) 215 (33.8)
NSTEMI, n (%) 225 (13.4) 268 (12.3) 79 (12.4)
STEMI, n (%) 140 (8.3) 194 (8.9) 51 (8.0)
Angiographic features
Multivessel disease, n (%) 310 (18.4) 390 (18.0) 119 (18.7) 0.99
Left main disease, n (%) 72 (4.3) 84 (3.9) 28 (4.4) 0.90
Left anterior descending artery, n (%) 998 (59.3) 1309 (60.3) 382 (60.1) 0.64
Type B2/C lesion, n (%) 1655 (74.5) 2116 (75.1) 617 (74.5) 0.96
Reference vessel diameter (mm) 2.99 ± 0.53 2.98 ± 0.65 3.04 ± 1.41 0.17
Minimal lumen diameter (mm) 0.62 ± 0.47 0.62 ± 0.44 0.62 ± 0.45 0.95
Diameter stenosis (%) 79.25 ± 17.92 78.89 ± 23.13 79.16 ± 14.65 0.83
Lesion length (mm) 24.7 ± 12.68 25.06 ± 12.97 24.08 ± 11.88 0.17
Procedural data
Bare metal stent, n (%) 2 (0.1) 4 (0.1) 1 (0.1)
0.37
First-generation drug-eluting stent, n (%) 3 (0.1) 7 (0.2) 2 (0.2)
Second-generation drug-eluting stent, n (%) 1636 (64.5) 2069 (63.6) 590 (61.8)
Third-generation drug-eluting stent, n (%) 803 (31.7) 1046 (32.1) 330 (34.6)
Stent diameter (mm) 3.03 ± 0.48 3.02 ± 0.45 3.02 ± 0.43 0.80
Stent length (mm) 24.27 ± 7.99 24.28 ± 8.27 23.92 ± 7.88 0.45
Stent number (/patient) 1.34 ± 0.63 1.31 ± 0.6 1.29 ± 0.58 0.53
P2Y12 reaction units 191.21 ± 76.98 221.46 ± 70.97 249.8 ± 71.01 <0.01
Other laboratory findings
Haemoglobin (g/dL) 13.6 ± 1.89 13.69 ± 1.8 13.66 ± 1.92 0.36
Platelet count (×1,000/µL) 228.02 ± 63.79 228.88 ± 63.83 225.72 ± 64.24 0.55
AST (IUI/L) 32.16 ± 36.16 32.33 ± 40.83 34.34 ± 50.19 0.50
ALT (IUI/L) 26.9 ± 31.56 25.18 ± 19.38 25.9 ± 24.12 0.12
Total cholesterol (mg/dL) 172.7 ± 45.89 173.1 ± 43.98 173.26 ± 45.72 0.95
LDL-C (mg/dL) 103.38 ± 36.68 104.29 ± 36.88 104.99 ± 38.05 0.64
HDL-C (mg/dL) 42.58 ± 11.53 42.6 ± 11.49 42.81 ± 11.3 0.91
Triglyceride (mg/dL) 142.47 ± 105.59 144.21 ± 93.71 139.1 ± 108.24 0.56
Fasting glucose (mg/dL) 128.73 ± 51.81 131.06 ± 51.77 131.73 ± 56.11 0.35
Creatinine (mg/dL) 1.04 ± 0.93 1.04 ± 0.87 1.28 ± 2.09 <0.01
hsCRP (mg/L) 4.64 ± 18.31 3.68 ± 13.09 5.19 ± 25.84 0.24
Left ventricular ejection fraction (%) 58.53 ± 11.08 59.06 ± 11.04 59.15 ± 11.02 0.30
Discharge medication
Aspirin, n (%) 1675 (99.6) 2157 (99.5) 632 (99.5) 0.77
Clopidogrel, n (%) 1647 (97.9) 2131 (98.3) 625 (98.4) 0.34
Proton pump inhibitor, n (%) 244 (14.5) 375 (17.3) 97 (15.3) 0.23
Statin, n (%) 1575 (93.6) 2018 (93.1) 605 (95.3) 0.36
ACE inhibitor, n (%) 472 (28.1) 571 (26.4) 163 (25.7) 0.17
ARB, n (%) 574 (34.2) 746 (34.4) 213 (33.7) 0.93
Beta-blocker, n (%) 1054 (62.7) 1300 (60.0) 402 (63.3) 0.70
Table 2. Baseline characteristics and procedural details. Data were presented as n (%) or mean ± standard 
deviation. Abbreviations: PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; 
NSTEMI, non-ST segment elevation myocardial infarction; STEMI, ST segment elevation myocardial infarction; 
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The present study also showed that low OPR by clopidogrel was insufficient to cause a clinically significant 
bleeding event. Some controversies exist between OPR and bleeding risk. The previous ADAPT-DES trial demon-
strated that low OPR increased the risk of bleeding event in US and European patients16. On the other hand, 
Liang et al. showed that OPR has no association with bleeding events in 1,016 Chinese ACS patients who took 
clopidogrel after DES implantation21. In recent years, concerns have been raised that the newer P2Y12 inhibitors 
may contribute to increased bleeding risk, especially in East Asian patients. With this concept in mind, our data 
may reflect the safety of clopidogrel in preventing bleeding events in East Asian patients.
The platelet function test (VerifyNow P2Y12 assay) and genotype test (CYP2C19 SNPs) were significantly 
associated with clinical outcomes in the present study. Clopidogrel resistance may be measured by platelet func-
tion test, but its reliability and intra-individual variability are quite questionable. Many factors such as smoking, 
food intake (i.e. caffeine and alcohol), fasting period, exercise, and circadian rhythm affect platelet functions22. 
On the contrary, genotype is invariant and the genotype test provides reliable genetic information from a very 
small amount of sample. Therefore, the genotype test, rather than the platelet function test, may offer more 
reliable information on clopidogrel resistance if a certain set of genotype strongly correlates with clopidogrel 
resistance.
The present study failed to show the significant relationship between OPR and other four SNPs (CYP2C9, 
PON1, ABCB1, and P2Y12). PON1 genetic polymorphism has been previously suggested to be associated with 
clopidogrel activity and its clinical efficacy8. P-glycoprotein-encoding MDR1 (ABCB1) genetic polymorphism 
showed poor clinical outcomes, which were probably mediated through the attenuation of clopidogrel absorp-
tion7,9. CYP2C9*3 loss-of-function allele, which affects the secondary metabolic step of clopidogrel activa-
tion, was related with stent thrombosis10,23. P2Y12 platelet ADP receptor G52T SNP was also reported to be 
associated with clopidogrel resistance11. However, most of those data were limited for Western patients24, sug-
gestive of the ethnic discrepancy between the East Asian and Western patients, similar to CYP2C19 genetic 
polymorphism.
The present study clearly showed that only CYP2C19 SNPs had a significant effect on OPR (Table 1). Among 
CYP2C19 SNPs, the prevalence of CYP2C19*17, reported to be associated with the enhanced platelet response to 
clopidogrel, was very low (1.2%) and its presence had no significant effect on OPR, similar to the other data from 
East Asian patients25. On the other hand, CYP2C19 loss-of-function alleles (*2 and *3) were significantly associ-
ated with poor clinical outcomes, consistent with previous results7,13,14,23,26,27. Choi et al. recently reported that a 
CYP2C19 loss-of-function allele affected clinical outcomes only in patients with first-generation DES implants28. 
They failed to show statistical significance in patients with newer-generation DES implantation. However, only 
one case of stent thrombosis occurred in a non-carrier of CYP2C19 loss-of-function allele as compared to five 
cases in carriers after implantation of the newer-generation DES. The absolute number of composite events was 
higher in carriers as compared with non-carriers. Thus, the sample size may be too small to determine the statis-
tical significance as compared with the present study.
The present study has several limitations. First, the VerifyNow test was performed only once in the present study. 
There were no data available regarding the platelet reactivity at the time of cardiovascular events. Thus, there exists 
a lack of direct evidence that the higher rate of cardiac death in patients with CYP2C19 genetic variants may be 
elicited by high OPR. In addition, we cannot rule out the possibility that CYP2C19 polymorphism directly affects 
cardiac death, independent of clopidogrel metabolism and the related platelet response. Indeed, the present study 
showed that other genetic polymorphisms of drug-metabolising enzymes had no association with platelet reactivity. 
Second, the present study analysed the clinical events during a 1-year follow-up period of DAPT. Further long-term 
investigation may provide insight into the clinical impact of genotype according to clopidogrel maintenance or dis-
continuation. Third, this study had more than one primary endpoint, including death and non-fatal MI. Death was 
further categorised into all-cause death and cardiac death. Although the endpoints were predefined, these multiple 
endpoints may make the study purpose unclear. Thus, the present study produced quite descriptive results.
In conclusion, the present study, which included approximately 5,000 PCI patients, demonstrated that the 
reduced function of CYP2C19 is related to high OPR, leading to increased thrombotic events in patients on 
clopidogrel after PCI. After adjustment, two copies of CYP2C19 loss-of-function alleles were found as independ-
ent prognosticators for cardiac death. Genotype-directed individualisation of antiplatelet therapy remains to be 
further investigated for East Asian patients.
Methods
Study population. Genotyping influences outcomes of coronary artery stenting (GENIUS) is a prospective, 
multicentre, observational study, which enrolled 5,000 patients undergoing PCI for coronary artery disease in 20 
tertiary hospitals in Korea between February 2012 and July 2014. The consumption of both aspirin (100 mg daily) 
and clopidogrel (75 mg daily) was recommended for 1 year (3 months minimum) after index PCI. Ticagrelor, 
prasugrel, warfarin, and other new oral anticoagulants were not used during the follow-up period. The study pro-
tocol was approved by the Institutional Review Board at each participating centre. Written informed consent was 
obtained from each patient at enrolment. The study complied with the Declaration of Helsinki and was registered 
with ClinicalTrials.gov (number NCT02707445).
AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDL-C, low-density lipoprotein cholesterol; 
HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; ACE inhibitor, 
angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker. *R represents *2 or *3.
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From the initial cohort of 5,000 patients, 4,587 patients were included in the first analysis (Analysis 1), which 
screened and selected the most powerful SNPs after excluding the following: inclusion/exclusion criteria violation 
(n = 81), follow-up loss (n = 107), consent withdrawal (n = 8), missing genotyping results (n = 26), and missing plate-
let function test results (n = 378). We focused on CYP2C19 genotype and undertook a second analysis (Analysis 2) 
on the remaining 4,489 patients after excluding the 98 patients with CYP2C19 gain-of-function alleles (Fig. 2).
Laboratory tests. The inhibitory effect of clopidogrel on platelet reactivity was measured using the 
VeriyfyNow P2Y12 assay (Accumetrics, San Diego, California, USA). The results were reported as PRU. SNPs 
measured were CYP2C19*2 (rs4244285), CYP2C19*3 (rs4986893), CYP2C19*17 (rs12248560), CYP2C9*3 
(rs1057910), ABCB1 (rs1045642), PON1 (rs662), and P2Y12 (rs6809699). The genotype of each SNP was deter-
mined by pyrosequencing using a PSQ 96MA Pyrosequencer (Pyrosequencing AB, Uppsala, Sweden), as previ-
ously reported29. The residual platelet reactivity and genotype results were blinded to the physicians and patients.
Definitions. Primary endpoints were death and non-fatal MI. Secondary endpoints were stent thrombosis, 
ischemic stroke, repeat revascularisation, and bleeding. Stent thrombosis was defined as definite, probable, or 
possible stent thrombosis based on the Academic Research Consortium Criteria30. MATE was considered as a 
composite endpoint for the ischemic event and defined as the composite of cardiac death, non-fatal MI, ischemic 
stroke, and stent thrombosis. Bleeding events were categorised according to the definitions of BARC31.
Statistics. Sample size was calculated based on previous trials performed in Korea27,32. Assuming a 10% 
difference among patients with CYP2C19 genetic variants and a 5% drop-out rate, a total of 4,924 patients 
were required to achieve 95% power to detect statistically significant differences among the groups using the 
Bonferroni multiple comparison test at a 0.05 significance level. Comparisons between groups were performed 
using the independent Student’s t-test or analysis of variance (ANOVA) test for continuous variables and χ2 
test for categorical variables. An ROC curve analysis was used to determine the probability of OPR for MATE. 
Figure 1. Multivariate Cox proportional hazard model. Cumulative event rates of (A) cardiac death, (B) major 
adverse thrombotic event (MATE), and (C) bleeding according to CYP2C19 genotype status. *R indicates *2 
and *3. HR, hazard ratio; 95% CI, 95% confidence interval.
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Figure 2. Study scheme. SNP, single nucleotide polymorphism; PRU, P2Y12 reaction unit; OPR, on-treatment 
platelet reactivity; MI, myocardial infarction.
Group 1(*1/*1) 
n = 1682
Group 2 (*1/*R) 
n = 2171
Group 3 (*R/*R) 
n = 636 p-value
In-hospital mortality, n (%) 1 (0.1) 0 (0) 2 (0.3) 0.15
1-year clinical events
Primary endpoints
All death, n (%) 25 (1.5) 41 (1.9) 19 (3.0) 0.03
Cardiac death, n (%) 12 (0.7) 30 (1.4) 13 (2.0) 0.01
Non-fatal MI, n (%) 16 (1.0) 25 (1.2) 7 (1.1) 0.64
Secondary endpoints
Stent thrombosis†, n (%) 2 (0.1) 9 (0.4) 4 (0.6) 0.04
Ischemic stroke, n (%) 10 (0.6) 11 (0.5) 4 (0.6) 0.96
Repeat revascularisation, n (%) 121 (7.2) 151 (7.0) 42 (6.6) 0.62
MATE‡, n (%) 38 (2.3) 68 (3.1) 21 (3.3) 0.10
Bleeding§, n (%) 33 (2.0) 38 (1.8) 15 (2.4) 0.74
Any transfusion, n (%) 53 (3.2) 63 (2.9) 24 (3.8) 0.65
Table 3. In-hospital and 1-year clinical outcome. *Data were presented as n (%). Abbreviations: MI, myocardial 
infarction; MATE, major adverse thrombotic event. *R represents *2 or *3. †Stent thrombosis included definite 
or possible stent thrombosis according to ARC criteria. ‡MATE, defined as the composite of cardiac death, non-
fatal MI, stent thrombosis, and ischemic stroke. §Bleeding was defined as a clinical bleeding event acceptable for 
BARC classification type 3, 4, or 5.
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The optimal cut-off value was estimated using the Youden index. The Cox proportional hazard model analyses 
were performed to compare the incidence of the clinical outcome groups. Multivariable Cox proportional haz-
ard regression model was used to identify risk predictors for MATE and cardiac death. The risk factors were 
age, sex, body mass index, current smoker, diabetes mellitus, prior coronary artery bypass graft, ACS, multives-
sel involvement, number of stents, left ventricular ejection fraction, haemoglobin level, creatinine level, and 
low-density lipoprotein cholesterol level. The results were expressed as HR with a 95% CI and p-value. All tests 
were two-tailed, and p-values less than 0.05 were considered statistically significant. All statistical analyses were 
performed using SAS (v9.3, SAS institute Inc., USA).
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